(Q46884993)

26 December 2017

title

Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning (English)

1 reference

26 December 2017

0 references

10

1 reference

26 December 2017

Koen van Besien

11

1 reference

26 December 2017

author name string

J Kline

1

1 reference

26 December 2017

D A Pollyea

2

1 reference

26 December 2017

W Stock

3

1 reference

26 December 2017

A Artz

4

1 reference

26 December 2017

E Rich

5

1 reference

26 December 2017

L Godley

6

1 reference

26 December 2017

T Zimmerman

7

1 reference

26 December 2017

K Thompson

8

1 reference

26 December 2017

K Pursell

9

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

26 December 2017

Bone Marrow Transplantation

published in

1 reference

26 December 2017

volume

37

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

307-310

1 reference

26 December 2017

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705249

Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705249

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705249

Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705249

Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705249

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705249

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705249

Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705249

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705249

inferred from DOI database lookup

7 January 2021

based on heuristic

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705249

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.BMT.1705249

1 reference

26 December 2017

1 reference

26 December 2017